RNAZ Profile
TransCode Therapeutics, Inc. is an innovative RNA-focused oncology company dedicated to advancing the development and commercialization of novel drugs and diagnostics aimed at treating and identifying metastatic diseases. Based in Boston, Massachusetts, TransCode Therapeutics specializes in harnessing the power of ribonucleic acid (RNA) technology to address complex cancer challenges. The company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b, a key regulator of metastatic cell viability implicated in several cancers, including breast, pancreatic, ovarian, colon cancers, and glioblastomas. By inhibiting this master regulator, TTX-MC138 aims to disrupt cancer metastasis and improve patient outcomes.
In addition to TTX-MC138, TransCode is developing several other cutting-edge RNA-based therapies. TTX-siPDL1 is an siRNA-based modulator designed to inhibit programmed death-ligand 1 (PD-L1), a protein that helps tumors evade the immune system. This approach aims to enhance immune system recognition and destruction of cancer cells. Another promising candidate, TTX-siLIN28B, is an siRNA-based inhibitor targeting the RNA-binding protein LIN28B, which is involved in regulating multiple cancer-related processes.
The company is also advancing TTX-RIGA, an RNA-based agonist of the retinoic acid-inducible gene I (RIG-I), which is designed to activate innate immunity within the tumor microenvironment. This approach seeks to boost the body’s natural immune response against cancer cells. Additionally, TransCode is developing TTX-CRISPR, a CRISPR/Cas9-based therapy platform aimed at repairing or eliminating cancer-causing genes within tumor cells. Another significant initiative is TTX-mRNA, an mRNA-based platform for creating cancer vaccines that trigger cytotoxic immune responses against tumor cells, potentially offering a new avenue for cancer prevention and treatment.
Founded in 2016, TransCode Therapeutics is at the forefront of integrating advanced RNA technologies with innovative cancer therapies. The company’s diverse pipeline reflects its commitment to addressing unmet needs in oncology through cutting-edge science and precision medicine. As it continues to develop and refine its therapeutic platforms, TransCode aims to revolutionize cancer treatment and improve outcomes for patients with metastatic and complex cancers.
|
